Therapeutic area intelligence for Addiction Medicine with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Clinical →

FDA →

Recent signals(3)

ClinicalJune 30, 2026

Study on Social Risk-Informed Care for Opioid Use Disorder in ED

A clinical trial is evaluating a new clinical decision support tool aimed at improving treatment adherence for opioid use disorder in the emergency department.

ClinicalJune 29, 2026

Clinical Trial on Extended-release Buprenorphine for Opioid Use Disorder Induction

A clinical trial is underway to evaluate the safety and pharmacokinetics of extended-release buprenorphine as a low-dose induction strategy for Opioid Use Disorder.

RegulatoryJune 11, 2026

FDA Clears Bridge Device for Opioid Use Disorder Treatment; Efficacy Under Evaluation

The Bridge Device has received FDA clearance for the treatment of Opioid Use Disorder, emphasizing safety over efficacy.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Opioid Use Disorder →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.